AnaptysBio
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Ro...
Latest News
4 days ago · zacks.com
AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue EstimatesAnaptysBio, Inc. (ANAB) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.52 per share a year ago.
4 days ago · globenewswire.com
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business UpdateSAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the fiscal first quarter ended September 30, 2026, and provided a business update.
6 days ago · globenewswire.com
Anaptys Announces Participation in Upcoming Investor ConferencesSAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
18 days ago · seekingalpha.com
Riverwater Micro Opportunities Strategy Q3 2026 Portfolio ActivityWe initiated a position in 908 Devices, a maker of portable chemical detection instruments used by hazmat teams, law enforcement, firefighters, and the military. We initiated a position in Bowhead Specialty Holdings, a specialty insurer founded in 2020 by industry veteran Stephen Sills. We exited Coastal Financial in July. Our thesis rested on its role as a banking partner to fintech companies and the operating leverage those partnerships were expected to deliver this year.
19 days ago · seekingalpha.com
Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And DetractorsThe Fund declined 4.75% while the Russell 2500 Index declined 6.37%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Knife River and Red Rock Resorts.
21 days ago · zacks.com
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 months ago · zacks.com
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue EstimatesAnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.34 per share a year ago.
2 months ago · globenewswire.com
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business UpdateSAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.
4 months ago · seekingalpha.com
AnaptysBio: The Royalty Waterfall Is About To ReverseAnaptysBio is now a focused royalty management company, with its value tied primarily to Jemperli royalties from GSK. Post-spin, ANAB operates virtually with a 95% targeted EBIT margin and over $140M net cash, eliminating prior R&D burn. Jemperli royalties escalate with sales, and once the Sagard obligation is paid (expected by mid-2027), ANAB will retain high-margin, growing royalty streams.
6 months ago · zacks.com
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ANAB